Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.39 |
| ▸ | ELANE | P08246 | 5/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | KLK3 | P07288 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13302626 | 0.89 | ELANE (0.46) | FOLH1FKBP1AELANE | |
| SCHEMBL16989188 | 0.88 | FOLH1 (0.40) | FOLH1FKBP1AELANECTSLKLK3 | |
| SCHEMBL16998961 | 0.88 | FOLH1 (0.40) | FOLH1FKBP1AELANECTSLKLK3 | |
| SCHEMBL7427227 | 0.84 | FOLH1 (0.43) | FOLH1FKBP1AELANECTSLKLK3 | |
| SCHEMBL16989180 | 0.82 | FOLH1 (0.39) | FOLH1FKBP1AELANECTSLKLK3 | |
| SCHEMBL16989257 | 0.82 | FOLH1 (0.38) | FOLH1FKBP1AELANE | |
| SCHEMBL7426204 | 0.81 | FKBP1A (0.44) | FOLH1FKBP1AELANECTSL | |
| SCHEMBL16989152 | 0.81 | FOLH1 (0.39) | FOLH1FKBP1AELANECTSLKLK3 | |
| SCHEMBL13302719 | 0.81 | FOLH1 (0.42) | FOLH1FKBP1AELANECTSLALDH1A1 | |
| SCHEMBL16989235 | 0.80 | FOLH1 (0.37) | FOLH1FKBP1AELANECTSLHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198673-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-10259785-B2 | Therapeutic compounds and compositions | EXITHERA PHARMACEUTICALS, INC. (US) | 2019-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11198673-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | FOLH1 1124/4885FKBP1A 2210/4885ELANE 57/4885 |
| US-10259785-B2 | Therapeutic compounds and compositions | KLK5, KLKB1, KLK2 | FOLH1 1124/4885FKBP1A 2210/4885ELANE 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.